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Abstract
Background. Steroids are largely effective for the immu-
nosuppressive treatment in renal transplant patients, but
cause severe side effects. Whether steroid withdrawal con-
fers long-term beneficial effects remains unclear.
Methods. Data on 4481 cadaveric kidney transplant reci-
pients were collected to estimate the impact of steroid
withdrawal on kidney function and graft and patient sur-
vival using multivariate Cox regression models.
Results. A total of 923 patients (20.6%) had steroid treat-
ment withdrawn. This was more common in recipients from
younger donors and in older recipients, and in recipientswith
a first transplant, thosewho had pre-transplant orde novo di-
abetes mellitus and those with fewer episodes of acute rejec-
tion (AR) (22.4% vs. 29.2%, P < 0.001). Cox multivariate
analysis stratifying by propensity scores showed that long-
term steroid therapy was associated with a 70% increase in
the risk of patient death. The repeatedmeasures linear model
showed that, although the abbreviated Modification of Diet
in Renal Disease (aMDRD) values changed over time (P =
0.002), this was independent of steroid withdrawal (P =
0.08). In addition, of the 772 (17.2%) recipients who devel-
oped de novo diabetes mellitus, 204 (26.4%) ceased antidia-
betic therapy, with more of these among those who ceased
steroids (23% vs. 33.3%,P= 0.003). Blood pressure, choles-
terol and triglyceride values were all significantly lower in
the patients who ceased steroids.
Conclusions. Steroid withdrawal in selected patients had
no negative effect over time on renal function and graft
survival, and it was associated with reduced mortality.
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Introduction
Steroids have proved to be very effective for immunosup-
pressive treatment in renal transplant patients, but long-
term therapy causes side effects leading to increased mor-
bidity, mortality and economic costs [1]. Accordingly, it is
of interest to reduce the dose of steroids, withdraw them
early or even use a steroid-free immunosuppressant proto-
col in the modern transplant era in order to improve kidney
transplant outcome [2].
In the era of cyclosporine (CsA), whether or not accom-
panied by azathioprine, steroids began to be withdrawn,
with the results showing that early withdrawal, black race
and renal function were all risk factors for acute rejection
(AR) and long-term graft loss [3,4]. In light of these data,
the European Best Practice Guidelines for Renal Trans-
plantation recommended that steroid withdrawal is safe on-
ly in low-risk patients and that, after withdrawal, renal
function should be monitored carefully because of the risk
of progressive worsening [5].
The introduction of mycophenolate mofetil (MMF) re-
duced the number of episodes of AR, and steroid withdra-
wal in low-risk patients treated with CsA and MMF did not
increase the incidence of AR, while renal function re-
mained stable [6]. The association of MMF and tacrolimus
(TAC) further lowered the incidence of AR and enabled
earlier and safer withdrawal of steroids. As an example, a
randomized study of steroid withdrawal 3 days after trans-
plantation in patients treated with MMF, TAC and induction
with daclizumab showed no significant differences in the
incidence of AR and renal function at 1year compared with
the control group [7]. In selected patients [stable renal func-
tion, no AR and panel-reactive antibody (PRA) <50%] trea-
ted with TAC, MMF and steroids who were randomized to
continue triple therapy or withdrawal of steroids beginning
3 months after transplantation, the incidence of AR was 6%
in patients who ceased steroids and 3% in those who were
maintained on steroids after 2 years of follow-up [8].
The aim of this retrospective cohort study was to ana-
lyse the effects of steroid withdrawal on renal function
and graft and patient survival in deceased donor kidney
transplantation performed in Spain since 1990.
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Materials and methods
Study design and patient population
This retrospective cohort study was carried out in all recipients from 34 of
the 38 adult kidney transplant centres in Spain. This population represents
96% of all adult recipients (≥18 years) who received a primary or repeat
deceased donor transplant performed during the calendar years 1990,
1994, 1998 and 2002 and who survived at least 1year, with a follow-up
until 31 December 2005. The quality of the data set was verified by ran-
dom examination of source documents at each of the participating trans-
plant centres.
A total of 4842 recipients, mostly Caucasian, were analysed, of whom
361 were excluded as they had not received an initial steroid therapy (n =
145) or due to lack of follow-up data (n = 131). The primary study end
point was to analyse the long-term effect of steroid withdrawal on kidney
function and graft and patient survival.
Institutional review and patient protection
Medical record review was performed according to the Spanish law on
clinical data confidentiality. This study was approved by the ethics com-
mittee of the hospital and was conducted according to the principles de-
scribed in the Declaration of Helsinki.
Clinical variables
The variables analysed included the cause of donor death (trauma or
stroke), age and gender of the donor and the recipient, body mass index
(BMI), first or re-transplantation, time on dialysis, PRA at peak and at
transplantation, human leucocyte antigen (HLA) mismatches, cold and
re-warm ischaemia times, delayed graft function (DGF), AR (pre and
post-steroid withdrawal), proteinuria, hepatitis C virus (HCV), diabetes
mellitus pre- and post-transplantation, therapy with statins, immunosup-
pression (intention to treat), kidney function, and graft and patient survival.
Definition of variables
Delayed graft function was defined as the requirement for dialysis during
the first week after transplantation, after ruling out accelerated or hyper-
acute rejection, vascular thrombosis and urinary tract obstruction. AR was
defined by the need for treatment, with or without biopsy confirmation.
Graft failure was defined as death or return to dialysis. The total number
of HLA mismatches was calculated as the sum of the mismatches in the
A, B and DR loci. New-onset diabetes after transplantation (NODAT) was
defined as the need for treatment with insulin or oral antidiabetic agents
after transplantation.
Immunosuppressive therapy
The patients in the 1990 and 1994 cohorts were treated with CsA and
prednisone, with or without azathioprine. Most of the 1998 cohort was
treated with CsA, MMF and prednisone, and the 2002 cohort was treated
with TAC, MMF and prednisone. Induction therapy with polyclonal or
monoclonal antibodies was received by 17.7% and 34% of the patients,
respectively.
Renal function
Renal allograft function was calculated from the serum creatinine mea-
surement, using the abbreviated Modification of Diet in Renal Disease
(aMDRD) equation [9].
Statistical analysis
Descriptive results are expressed as the mean ± standard deviation for
continuous variables. Comparisons of continuous variables between study
periods were made by the Mann–Whitney U-test. The chi-square test, or
Pearson, and Fisher's exact test when appropriate, were used for inter-
group comparisons of categorical variables. Kaplan–Meier survival
curves were used to estimate graft and patient survival, and the log-rank
test to compare survival curves. Univariate and multivariate Cox propor-
tional hazards regression models were used to identify baseline risk fac-
tors for graft failure and patient death. The following variables were
included in the model: recipient and donor age and gender, cause of donor
death, DGF, AR, PRA (≤15% vs. >15%), proteinuria (increase between 3
and 12 months), creatinine at 3 months and the creatinine delta (increase
between 3 and 12 months), diabetes mellitus before transplantation, NO-
DAT, re-transplant, therapy with statins, HCV-positive recipient, and mean
times to transplantation and steroid withdrawal. Steroid withdrawal was
introduced in the Cox regression model as a time-dependent variable.
When steroid withdrawal was significant in the univariate Cox model, a
multivariate Cox model was performed entering a propensity score as an
independent variable. This score was defined as the conditional probabil-
ity of steroids withdrawal during follow-up, based on the characteristic of
the recipient [10]. The estimated propensity scores, categorized into quin-
tiles, were used to stratify Cox regression analysis. A general linear model
for repeated measures was used to assess the effect of renal function, es-
timated by aMDRD, on survival. P-values of <0.05 were considered to
indicate statistical significance.
The SPSS program (version 15; Inc, Chicago, IL) was used as a data-
base and for the descriptive statistical analysis.
Results
Table 1 shows the significant demographic and back-
ground characteristics of patients with or without steroid
withdrawal. Steroids were withdrawn in 923 (20.6%) pa-
tients after a mean time of 3.7 ± 2.8 years (23.2% during
the first year). Table 2 shows the immunosuppressive treat-
ment and differences between the different cohorts. With
effect from the introduction of MMF, and later TAC
(1998 and 2002 cohorts), steroid suppression was earlier
and more usual. No significant differences were found in
cold ischaemia time, BMI, gender, PRA at the time of
transplant or the historical peak value or in HLA mis-
matches. The incidence of AR after steroid withdrawal
was 3%.
Graft survival
The Kaplan–Meier uncensored and death-censored graft
survival curves were significantly greater in the patients
who had steroids withdrawn. Mean graft survival was
13.6 vs. 12.6 years (P < 0.001) and 14.3 vs. 13.8 years
(P < 0.001), respectively. The multivariate Cox proportion-
al regression analysis showed that those patients who did
not cease steroids had a greater risk for death-censored
Table 1. Significant demographic and background characteristics of the
patients with and without steroid withdrawal
Steroid withdrawal
PNo Yes
Transplants (n) 3.558 923
Donor age (years) 42.7 ± 16.8 39.5 ± 16.8 <0.001
Recipient age (years) 46.1 ± 13.2 48.0 ± 13.1 <0.001
WIT (min) 46.7 ± 19.3 39.4 ± 19.3 <0.001
AR (%) 29.2 22.4 <0.001
Donor death (% stroke) 51.4 44.2 <0.001
Re-transplant (%) 13.5 8.1 <0.001
Diabetes mellitus (%) 4.7 9.9 <0.001
New-onset diabetes mellitus (%) 15.5 23.1 <0.001
MWT (years) 3.4 ± 3.8 2.9 ± 3.8 <0.001
WIT, warm ischaemia time; AR, acute rejection; MWT, mean wait for
transplantation.
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graft loss [relative risk (RR) 1.50, 95% confidence inter-
val, 1.21–1.85; P < 0.001].
The multivariate Cox model of factors predicting the rel-
ative risk of uncensored graft loss by propensity scores
showed that non-withdrawal of steroids represented an in-
creased risk of graft loss of 36% (Table 3) after adjusting
for other confounder variables, including transplant year.
However, when the model was censored for patient death,
the differences were not significant.
Patient survival
Kaplan–Meier patient survival (Figure 1) was significantly
greater in the patients who ceased steroids (P < 0.001).
Deaths occurred in 8.5% vs. 12.5% (P < 0.001), respec-
tively. Non-withdrawal of steroids was associated with a
higher risk for death (70%) in multivariate regression anal-
ysis (Table 4).
Special mention should be made of the analysis of the
1990 cohort after 15 years of follow-up. Of the 740 pa-
tients, 143 (19.3%) ceased steroids, with no differences be-
tween the two groups according to donor age, PRA, cold
ischaemia time, gender, AR during the first year, HLA or
Table 3. Multivariate Cox model (uncensored): factors predictive of the
risk of graft loss stratified by propensity scores
Beta
Standard
error
RR
(eBeta) 95% CI P
Recipient agea 0.45 0.09 1.58 1.32–1.89 <0.0001
HCVb 0.33 0.07 1.39 1.19–1.63 <0.0001
Re-transplantc 0.30 0.10 1.35 1.10–1.64 0.002
Donor aged 0.19 0.08 1.21 1.02–1.45 0.02
Acute rejectione 0.33 0.06 1.39 1.21–1.58 <0.0001
Statins at 1 yearf 0.21 0.08 1.23 1.04–1.47 0.01
Serum creatinine at
3 months
0.53 0.06 1.69 1.49–1.93 <0.0001
Delta of serum creatinine 0.67 0.04 1.96 1.80–2.13 <0.0001
Proteinuria at 3 months 0.15 0.02 1.16 1.10–1.23 <0.0001
Increase in proteinuria
from 3 to 12 months
0.22 0.02 1.24 1.17–1.31 <0.0001
Diabetes mellitusg
No post-transplant
diabetes
0.00 1
Pre-transplant diabetes 0.62 0.15 1.86 1.37–2.51 <0.0001
Post-transplant diabetes 0.48 0.12 1.62 1.26–2.08 0.0001
No steroid withdrawalh 0.31 0.09 1.36 1.44–1.63 0.0006
Included in the model but not in the table was transplant year (P > 0.05).
HCV, hepatitis C virus; DGF, delayed graft function; Delta of serum cre-
atinine, difference between 12 and 3 months; CI, confidence interval.
aRecipients <60 years.
bFirst transplant.
cHepatitis C virus negative.
dDonor <60 years.
eNo acute rejection.
fStatin treatment.
gNo pre-transplant diabetes mellitus.
hSteroid withdrawal.
Table 2. Immunosuppressive treatment in the different cohorts and data
related with steroid withdrawal
Year of transplantation
1990 1994 1998 2002
Transplants (n) 740 1040 1465 1236
CsA (%) 97.27 78.87 74.53 17.39
Az (%) 58.11 68.02 20.13 0.56
TAC (%) 0.13 0.77 12.08 66.66
Prednisone (%) 100 100 100 100
MMF (%) 0.13 0.58 62.59 79.77
ALA (%) 26.87 17.73 25.80 34.38
SRL (%) 2.38 3.31
Follow-up (years) 15 11 8 3
TPSW (%) 15 11 25.4 16.3
First year (%) 15.4 9.7 22 44.8
MTW (years) 6.1 ± 3.8 5.0 ± 2.6 3.2 ± 2.0 1.6 ± 0.8
ARSW (%) 5.4 3.9 0 3
CsA, cyclosporine; Az, azathioprine; TAC, tacrolimus; MMF, mycophe-
nolate mofetil; ALA, anti-lymphocyte antibodies; SRL, sirolimus; TPSW,
total percent of steroid withdrawal; MTW, mean time of steroid withdraw-
al; ARSW, acute rejection post-steroid withdrawal.
Fig. 1. Kaplan–Meier patient survival with and without steroid
withdrawal (log-rank test, P < 0.001).
Table 4. Cox multivariate model: factors predictive of the risk of death
stratified by propensity scores
Beta
Standard
error
RR
(eBeta) 95% CI P
Recipient agea 1.17 0.09 3.23 2.68–3.90 <0.0001
HCVb 0.32 0.10 1.38 1.13–1.70 0.0017
DGFc 0.18 0.09 1.20 1.00–1.44 0.04
Serum creatinine at
3 months
0.21 0.09 1.23 1.02–1.48 0.026
Delta of serum creatinine 0.25 0.08 1.29 1.10–1.51 0.0014
Proteinuria at 3 months 0.12 0.60 1.13 1.01–1.27 0.034
Increase in proteinuria
from 3 to 12 months
0.14 0.04 1.15 1.05–1.26 0.0001
Diabetes mellitusd
No post-transplant diabetes 0.00 1
Pre-transplant diabetes 0.68 0.19 1.97 1.35–2.87 0.0004
Post-transplant diabetes 0.45 0.16 1.58 1.15–2.16 0.0044
No steroid withdrawale 0.53 0.12 1.70 1.33–2.18 <0.0001
Included in the model but not in the table was transplant year (P > 0.05).
HCV, hepatitis C virus; DGF, delayed graft function; Delta of serum cre-
atinine, difference between 12 and 3 months; CI, confidence interval.
aRecipients <60 years.
bHepatitis C virus negative.
cNo DGF.
dNo pre-transplant diabetes mellitus.
eSteroid withdrawal.
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cause of donor death. Differences were found, however,
between those who did not and those who did cease steroid
therapy in recipient age (42.1 ± 12.2 vs. 45.8 ± 11.7 year,
P = 0.001), time on dialysis (3.7 ± 3.8 vs. 3.0 ± 3.0 years,
P = 0.04), re-transplant (11.7% vs. 4.2%, P = 0.008), pre-
transplant diabetes mellitus (1.2% vs. 9.5%, P < 0.001)
and NODAT (11.2% vs. 23.8%, P < 0.001). Again, non-
withdrawal of steroids was associated with a higher risk
for uncensored (RR 1.65, 95% confidence interval,
1.21–2.25; P = 0.001) and death-censored graft survival
(RR 1.48, 95% confidence interval, 1.03–2.13; P = 0.03)
as well as patient death (RR 1.66, 95% confidence inter-
val, 1.11–2.49; P = 0.01). The mean aMDRD at 1year in
the non-withdrawal and the withdrawal groups was similar
(52.4 ± 18.7 and 49.2 ± 19.3 mL/min/1.73 m2; P = 0.69,
respectively), remaining non-significant over time.
Renal function
The aMDRD was significantly greater at the time of
withdrawal in the patients who ceased steroids (except
in the 1990 cohort) and remained so during the follow-
up (P < 0.05). By applying a general linear model for
repeated means showed that aMDRD values changed
over time (P = 0.002), but independently of steroid with-
drawal (P = 0.08).
Cardiovascular risk factors
Pre-transplant diabetes mellitus was more prevalent in pa-
tients with steroid withdrawal (Table 1). A total of 772
(17.2%) patients developed NODAT. Of these, 204
(26.4%) stopped treatment with insulin or oral antidiabetic
agents during the post-transplant period, and the highest
percentage belonged to patients who discontinued steroids
(23% vs. 33.3%, P = 0.003).
Total cholesterol values were significantly lower in the
patients who ceased steroids from the first post-transplant
year (220.7 ± 46.4 vs. 214.4 ± 44.5 mg/dL, P = 0.001) to
the 10th year (211.7 ± 41.1 vs. 199.9 ± 34.1 mg/dL, P <
0.001). A similar situation was seen with the triglycerides
from the first year (152.2 ± 74.0 vs. 138.7 ± 65.6 mg/dL, P
< 0.001) to the 12th year (148.2 ± 81.8 vs. 118.8 ±
49.8 mg/dL, P = 0.008).
Finally, although the number of antihypertensive drugs
was significantly higher in patients who did not cease ster-
oids, both systolic and diastolic blood pressures were sim-
ilar during long-term follow-up.
Discussion
This retrospective cohort study carried out in adult renal
transplant units in Spain analysed the very long-term im-
pact of steroid withdrawal on renal function and graft and
patient survival. This is a hotly debated topic in the field of
renal transplantation that has been analysed by many in-
vestigators [11,12], although mostly focused on the short-
or medium-term risk–benefit ratio [8,13,14].
During the era of CsA, an early and rapid discontinua-
tion of steroids was associated with a high incidence of AR
and worsening renal function [15]. However, in favour of
early steroid withdrawal was the fact that certain side ef-
fects of steroids, once begun, progressed despite withdraw-
al. With this in mind, many studies of steroid withdrawal in
this period focused mainly on analysing which group of
patients could benefit from steroid suppression and with
effect from when [2,3], limiting the implementation of this
therapeutic strategy in routine clinical practice.
With the introduction of TAC and MMF, steroid with-
drawal in selected patients did not significantly increase
the risk of AR or influence graft or patient survival and
kidney function. Consequently, withdrawal began to take
place earlier and in more patients, as seen in this study
[16,17].
In support of these arguments, a prospective, multi-cen-
tre study of 1110 renal transplant patients with no immuno-
logical risk and with good renal function who discontinued
steroids after 6months showed increases of graft (81.9% ±
1.8% vs. 75.3% ± 1.2%, P = 0.0001) and patient survival
(88.8% ± 1.5% vs. 84.3% ± 1.0%; P = 0.0016), as well as a
reduction in cardiovascular risk factors [18].
Although in our study steroid withdrawal was later, un-
scheduled and under variable criteria, the results are simi-
lar to previous reports. Of note was the higher mortality in
the patients who did not cease steroids in all the multivar-
iate models tested and in all the cohorts studied. We con-
ducted an analysis of propensity for steroid withdrawal in
order to avoid selection bias with the elimination of ster-
oids based on clinical characteristics during follow-up. In
addition, steroid withdrawal was entered in the Cox model
as a time-dependent covariate. Thus, patients with no ste-
roid withdrawal showed a higher relative risk for uncen-
sored graft loss in the Cox regression analysis after
adjusting for other confounding covariates, including pro-
pensity score. Nevertheless, this was not observed when
death-censored graft analysis was assessed. A higher mor-
tality in the patients who continued steroids may explain
these differences.
The analysis of the 1990 cohort deserves special men-
tion. This cohort of 740 patients with a follow-up of
15 years experienced significantly higher mortality in
those who continued steroids, despite the fact that the other
group (who did cease steroids) had a higher recipient age
and greater proportion of diabetes mellitus. No differences
were found in the selection variables most commonly used
to withdraw steroids (good renal function and absence or
lower incidence of AR).
Steroid withdrawal is a usual clinical practice in Spain,
where selected patients only received 5 mg per day of
prednisone. Although this dosage may confer a low risk
for cardiovascular disease, it is possible that steroid sup-
pression could optimize the cardiovascular profile by re-
ducing risk factors for mortality such as blood pressure
or insulin resistance, especially in predisposed individuals.
In our study, elimination of steroids was associated with a
better control of glucose metabolism, lipid profile and
blood pressure compared with the recipients who contin-
ued steroids. Previous studies have demonstrated similar
findings [18–20].
Regarding renal function, steroid withdrawal did not
modify long-term graft function. Although renal function,
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evaluated by aMDRD, showed changes over time, this ef-
fect was independent of steroid withdrawal. This was ob-
served in all the cohorts analysed and confirms that this
therapeutic strategy may preserve renal function in the
long term, even in the presence of other risk factors.
In conclusion, this large retrospective study demonstrates
that, with effect from the era of CsA, steroid withdrawal in
renal transplant recipients does not have a negative impact
on graft function or survival, and is associated, in the long
term, with a significant reduction in mortality.
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